Patient-reported clinical control and peak-flow: Effects of 30 versus 6 month treatment with inhaled corticosteroids (ICS) with/without long-acting2 -agonists (LABA) in moderately severe COPD
J. B. Snoeck-Stroband, T. S. Lapperre, M. M. E. Gosman, W. J. J. Assendelft, H. M. Boezen, N. H. T. ten Hacken, T. van der Molen, P. S. Hiemstra, D. S. Postma, P. J. Sterk, J. K. Sont, The Glucold Study Group (Leiden, Groningen, Amsterdam, Netherlands)
Source: Annual Congress 2011 - Disease management in specific primary care populations
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. B. Snoeck-Stroband, T. S. Lapperre, M. M. E. Gosman, W. J. J. Assendelft, H. M. Boezen, N. H. T. ten Hacken, T. van der Molen, P. S. Hiemstra, D. S. Postma, P. J. Sterk, J. K. Sont, The Glucold Study Group (Leiden, Groningen, Amsterdam, Netherlands). Patient-reported clinical control and peak-flow: Effects of 30 versus 6 month treatment with inhaled corticosteroids (ICS) with/without long-acting2 -agonists (LABA) in moderately severe COPD. Eur Respir J 2011; 38: Suppl. 55, 4614
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: